Chiara Bastiancich

Dr. Chiara Bastiancich

UMR7051 Institut de Neurophysiopathologie, Aix-Marseille Université, France
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in Journal of Controlled Release
Verified
Journal Article
Closed access
Chiara BastiancichChiara Bastiancich
Chiara Bastiancich
PDP. Danhier
P. Danhier
VPVéronique Préat
Véronique Préat
FDF. Danhier
F. Danhier

1 October 2017 in Journal of Controlled Release
Verified
Journal Article
Closed access
Chiara BastiancichChiara Bastiancich
Chiara Bastiancich
JBJohn Bianco
John Bianco
KVK. Vanvarenberg
K. Vanvarenberg
BUB. Ucakar
B. Ucakar
NJN. Joudiou
N. Joudiou
FDF. Danhier
F. Danhier

1 March 2016 in Journal of Controlled Release
Verified
Journal Article
Closed access
Chiara BastiancichChiara Bastiancich
Chiara Bastiancich
KVK. Vanvarenberg
K. Vanvarenberg
BUB. Ucakar
B. Ucakar
MPM. Pitorre
M. Pitorre
GBGuillaume Bastiat
Guillaume Bastiat
FDF. Danhier
F. Danhier

1 October 2021 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
Chiara BastiancichChiara Bastiancich
Chiara Bastiancich
AMAlessio Malfanti
Alessio Malfanti
VPVéronique Préat
Véronique Préat
RRRuman Rahman
Ruman Rahman

1 August 2018 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
LGLakshmi Pallavi Ganipineni
Lakshmi Pallavi Ganipineni
BUBernard Ucakar
Bernard Ucakar
NJNicolas Joudiou
Nicolas Joudiou
JBJohn Bianco
John Bianco
PDPierre Danhier
Pierre Danhier
VPVéronique Préat
Véronique Préat
Introduction: Glioblastoma (GBM) therapy is highly challenging, as the tumors are very aggressive due to infiltration into the surrounding normal brain tissue. Even a combination of the available therapeutic regimens may not debulk the tumor completely. GBM tumors are also known for recurrence, resulting in survival rates averaging <18 months. In addition, systemic chemotherapy for GBM has been challenged for its minimal desired therapeutic effects and unwanted side effects. Purpose: We hypothesized that paclitaxel (PTX) and superparamagnetic iron oxide (SPIO)-loaded PEGylated poly(lactic-co-glycolic acid) (PLGA)-based nanoparticles (NPs; PTX/SPIO-NPs) can serve as an effective nanocarrier system for magnetic targeting purposes, and we aimed to demonstrate the therapeutic efficacy of this system in an orthotopic murine GBM model. Materials and methods: PTX/SPIO-NPs were prepared by emulsion–diffusion–evaporation method and characterized for physicochemical properties. In vitro cellular uptake of PTX/SPIO-NPs was evaluated by fluorescence microscopy and Prussian blue staining. Orthotopic U87MG tumor model was used to evaluate blood–brain barrier disruption using T1 contrast agent, ex vivo biodistribution, in vivo toxicity and in vivo antitumor efficacy of PTX/SPIO-NPs. Results: PTX/SPIO-NPs were in the size of 250 nm with negative zeta potential. Qualitative cellular uptake studies showed that the internalization of NPs was concentration dependent. Through magnetic resonance imaging, we observed that the blood–brain barrier was disrupted in the GBM area. An ex vivo biodistribution study showed enhanced accumulation of NPs in the brain of GBM-bearing mice with magnetic targeting. Short-term in vivo safety evaluation showed that the NPs did not induce any systemic toxicity compared with Taxol® (PTX). When tested for in vivo efficacy, the magnetic targeting treatment significantly prolonged the median survival time compared with the passive targeting and control treatments. Conclusion: Overall, PTX/SPIO-NPs with magnetic targeting could be considered as an effective anticancer targeting strategy for GBM chemotherapy.

20 March 2019 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Monica ArgenzianoMonica Argenziano
Monica Argenziano
Adam HaimhofferAdam Haimhoffer
Adam Haimhoffer
Chiara BastiancichChiara Bastiancich
Chiara Bastiancich
Laszlo JicsinszkyLaszlo Jicsinszky
Laszlo Jicsinszky
Fabrizio CalderaFabrizio Caldera
Fabrizio Caldera
RCRoberta Cavalli
Roberta Cavalli
Imiquimod (IMQ) is an immune response modifier clinically used for the treatment of various topical diseases. However, its poor aqueous solubility and skin penetration capability make the topical delivery of IMQ a challenging task. This work aims at developing a nanomedicine-based topical formulation, carrying IMQ to control the scarring process for the treatment of aberrant wounds. For this purpose, IMQ was loaded in β-cyclodextrin-based nanosponges and dispersed in a hydrogel suitable for dermal application. The formulation was characterized in vitro and compared with IMQ inclusion complexes, with (2-hydroxy)propyl β-cyclodextrin(HPβCD) and carboxymethyl β-cyclodextrin (CMβCD) showing enhanced penetration properties. The hydrogel containing IMQ-loaded nanosponges could act as a drug reservoir and guarantee the sustained release of IMQ through the skin. A greater inhibitory effect on fibroblast proliferation was observed for IMQ loaded in nanosponges compared to the other formulations.